Document is current
Any future updates will be listed below
-
Authors
Taieb, Julien https://orcid.org/0000-0002-9955-4753
Ambrosini, Margherita https://orcid.org/0000-0003-4131-2409
Alouani, Emily
Lonardi, Sara https://orcid.org/0000-0002-7593-8138
Sinicrope, Frank A
Decraecker, Marie
Boileve, Alice
Hafliger, Emilie
Mazard, Thibault
Pernot, Simon
Parent, Pauline
Ros, Javier
Overman, Michael J https://orcid.org/0000-0001-5377-135X
Jayachandran, Priya
Nasca, Vincenzo
Salvatore, Lisa
Guimbaud, Rosine
Cremolini, Chiara
Tougeron, David https://orcid.org/0000-0002-8065-9635
Pietrantonio, Filippo https://orcid.org/0000-0002-8530-8420
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02821013 at ClinicalTrials.govisrctn15837212 at ISRCTN.orgDocuments that mention this clinical trial
Considerations for treatment duration in responders to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2020-001901
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
https://doi.org/10.1136/jitc-2020-001781
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
nct05255302 at ClinicalTrials.govDocuments that mention this clinical trial
Considerations for treatment duration in responders to immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2020-001901
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
https://doi.org/10.1136/jitc-2020-001781
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
nct05692999 at ClinicalTrials.govDocuments that mention this clinical trial
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
nct04909684 at ClinicalTrials.govDocuments that mention this clinical trial
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
nct04913025 at ClinicalTrials.govDocuments that mention this clinical trial
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
Documents that mention this clinical trial
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2024-010424
- License Information
